Lexibulin (CYT997) is primarily investigated for its potential in cancer treatment due to its ability to inhibit microtubule dynamics. This mechanism disrupts the division of cancer cells, leading to their death. It has been studied in various types of cancers, including solid tumors and hematologic malignancies, showing promise in preclinical and early-phase clinical trials. Additionally, Lexibulin has been explored for its vascular-disrupting properties, which can target the blood supply to tumors, further enhancing its anticancer effects. Research continues to evaluate its efficacy and safety in combination with other therapies to improve treatment outcomes.